Monday 19 October 2026
Export MOTS’s income statement to Excel — free account
Motus GI Holdings, Inc.
MOTS Healthcare Medical Devices
Motus GI Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $319,000.00, down 46.1% from fiscal 2022. Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow MOTS
| Mar '24 | Dec '23 | Sep '23 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
11.59 | 3.30 | 12.57 | 9.11 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.87) | (0.57) | (2.33) | (1.97) | |
P/B ratio |
1.24 | 0.39 | 0.00 | 0.00 | |
Price to Tangible BV |
1.24 | 0.39 | 0.00 | 0.00 | |
EV/Sales |
3.51 | (5.12) | 22.09 | 11.43 | |
EV/EBITDA |
0.00 | 0.15 | 0.00 | 0.00 | |
EV/Operating CF |
(0.14) | 0.15 | (0.60) | (0.42) | |
EV/FCF |
(0.13) | 0.14 | (0.60) | (0.42) | |
Quick Ratio |
1.52 | 1.54 | 1.29 | 1.94 | |
Current Ratio |
1.74 | 1.76 | 1.49 | 2.20 | |
Net Debt/EBITDA |
1.43 | 1.20 | (1.60) | (0.52) | |
Debt/Assets |
32.56% | 31.46% | 108.20% | 83.57% | |
Debt/Equity |
0.75 | 0.85 | (3.71) | (10.19) | |
Asset Turnover |
0.03 | 0.03 | 0.03 | 0.03 | |
Operating CF/Net income |
0.27 | 0.66 | 0.73 | 0.86 | |
Capex/Depreciation |
0.00 | 0.00 | (0.07) | (0.22) | |
Interest Coverage |
(25.32) | (45.78) | (10.78) | (10.90) | |
Research and Development Expense of Revenue |
710.94% | 876.56% | 805.81% | 671.68% | |
Selling, General and Administrative Expense of Revenue |
2,535.94% | 2,639.06% | 2,022.09% | 1,747.79% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
110.94% | 167.19% | 108.14% | 43.36% | |
Graham Net Nets |
0.46 | 1.16 | (0.92) | (0.57) | |
Graham Number |
0.00 | 0.00 | 56.56 | 49.49 | |
Earnings Yield |
(3,553.86%) | (2,196.15%) | (491.30%) | (566.88%) | |
Free Cash Flow Yield |
(224.79%) | (1,072.93%) | (294.77%) | (301.90%) | |
Revenue per Share |
0.01 | 0.08 | 0.14 | 0.22 | |
Operating CF per Share |
(0.23) | (2.29) | (3.14) | (5.10) | |
Capex per Share |
0.00 | 0.00 | (0.03) | (0.10) | |
Free Cash Flow per Share |
(0.23) | (2.29) | (3.16) | (5.20) | |
Cash per Share |
0.57 | 6.12 | 9.14 | 16.91 | |
Shareholders Equity per Share |
0.36 | 3.32 | (3.96) | (1.91) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.36 | 3.32 | (3.96) | (1.91) | |
Free Cash Flow |
(2.02) | (1.86) | (1.98) | (2.62) | |
Working Capital |
2.44 | 2.49 | 2.21 | 5.36 | |
Capital Expenditures |
— | 0.00 | (0.02) | (0.05) | |
Net Current Asset Value |
1.75 | 1.22 | (4.23) | (2.89) | |
EV/EBIT |
0.00 | 0.14 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.19 | 0.43 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.07 | 0.07 | 0.13 | 0.09 | |
Average Payables |
1.48 | 1.91 | 2.08 | 1.84 | |
Average Inventory |
0.35 | 0.37 | 0.71 | 0.74 | |
Average Assets |
9.65 | 12.44 | 12.93 | 15.91 | |
Average Common Equity |
0.99 | 2.83 | (0.86) | 1.50 |
Columns are period end dates